Role of US military research programs in the development of US Food and Drug Administration--approved antimalarial drugs
Related Experiment Video
Updated: Aug 8, 2026

Visualizing Efficacy of Pesticides Against Disease Vector Mosquitoes in the Field
Published on: March 16, 2019
Lynn W Kitchen1, David W Vaughn, Donald R Skillman
1Military Infectious Diseases Research Program, US Army Medical Research and Materiel Command, Fort Detrick, MD 21702-5012, USA. lynn.kitchen@amedd.army.mil
Abstract:
US military physicians and researchers helped identify the optimum treatment dose of the naturally occurring compound quinine and collaborated with the pharmaceutical industry in the development and eventual US Food and Drug Administration approval of the synthetic antimalarial drugs chloroquine, primaquine, chloroquine-primaquine, sulfadoxine-pyrimethamine, mefloquine, doxycycline, halofantrine, and atovaquone-proguanil. Because malaria parasites develop drug resistance, the US military must continue to support the creation and testing of new drugs to prevent and treat malaria until an effective malaria vaccine is developed. New antimalarial drugs also benefit civilians residing in and traveling to malarious areas.
Related Concept Videos
Drug Regulation
Antiprotozoal Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Anthelminthic Agents
Drug Control Governance: Regulatory Bodies and Their Impact
Malaria

